FSUE “Endopharm” has received a Certificate of Compliance with the Good Manufacturing Practice (GMP) requirements of the Ministry of Health of the Republic of Serbia, opening up opportunities for the Company to enter the Serbian pharmaceutical market.
The setup and outfit of the production, as well as the processes for ensuring and monitoring the quality of drugs produced at Endopharm’s production sites were comprehensively assessed during the inspection carried out by authorized specialists of the regulatory body of the Republic of Serbia.
The production of more than 140 medical product names in various fields of medicine is organized at the inspected sites: anesthesiology, ophthalmology, cardiology, psychiatry, gynecology, neurology, gastroenterology, most of which are included in the Vital and Essential Drugs List, including a line of centrally acting analgesics presented in a wide range of dosage forms.
Compliance with GMP requirements has been confirmed, inter alia, for the production of various types of active pharmaceutical substances from raw materials of animal and plant origin, extracted by biotechnological and chemical synthesis methods.
The Certificate of Compliance of the drug manufacturer FSUE “Endopharm” with the GMP requirements of the Ministry of Health of the Republic of Serbia (Certificate No. 64 dated September 27, 2023) will enhance the export potential of the Company’s products.
Comment type is not specified in the component properties.